Camurus AB (publ) (LON:0RD1)
London · Delayed Price · Currency is GBP · Price in SEK | Market Cap | 3.05B |
| Revenue (ttm) | 185.85M |
| Net Income (ttm) | 61.71M |
| Shares Out | n/a |
| EPS (ttm) | 1.03 |
| PE Ratio | 49.49 |
| Forward PE | 27.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,747 |
| Average Volume | 15,608 |
| Open | 639.00 |
| Previous Close | 614.83 |
| Day's Range | 635.50 - 651.50 |
| 52-Week Range | 496.80 - 749.00 |
| Beta | 0.48 |
| RSI | 60.75 |
| Earnings Date | Feb 12, 2026 |
About Camurus AB
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocri... [Read more]
Financial Performance
In 2024, Camurus AB's revenue was 1.87 billion, an increase of 8.78% compared to the previous year's 1.72 billion. Earnings were 428.39 million, a decrease of -0.71%.
Financial numbers in SEK Financial StatementsNews
Camurus reports positive topline results for CAM2056, semaglutide monthly depot
CAM2056 showed weight and A1c reductions comparable to or exceeding those seen for weekly semaglutide (Wegovy®) Results include a 9.3% weight reduction with CAM2056 vs. 5.2% with weekly semaglutide at...
Camurus AB (publ) (CAMRF) Q3 2025 Earnings Call Transcript
Camurus AB (publ) 2025 Q3 - Results - Earnings Call Presentation
Camurus AB (FRA:7CA) Q3 2025 Earnings Call Highlights: Strong Profit Growth Amid Revenue ...
Camurus AB (FRA:7CA) Q3 2025 Earnings Call Highlights: Strong Profit Growth Amid Revenue Guidance Adjustment
Q3 2025 Camurus AB Earnings Call Transcript
Q3 2025 Camurus AB Earnings Call Transcript
Camurus AB (publ) reports Q3 results
Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients
CAM2029 reduces liver and cyst volume growth compared to placebo Well tolerated with no new or unexpected safety findings A follow-up Phase 3 study will be discussed with regulatory authorities LUND,...
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal® technology and Eli Lilly's proprietary drug compounds Camurus eligible to receive up to $870 million in pote...
CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU
LUND, Sweden , April 25, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positi...
US FDA declines to approve Camurus' rare hormone disorder drug
The U.S. Food and Drug Administration has declined to approve Camurus' drug for the treatment of a rare hormonal disorder due to deficiencies at a third-party manufacturing facility, the Swedish drugm...
New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl
LUND, Sweden , June 25, 2024 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized, double-blind, Phase 3...